Published C6mPhE-383 LNP composition
Component: C6mPhE-383 | mol%: 35 | Role: Ionizable lipid
sales@dcchemicals.com
C6mPhE-383
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Published C6mPhE-383 LNP composition
Component: DOPE | mol%: 16 | Role: Helper phospholipid
Published C6mPhE-383 LNP composition
Component: Cholesterol | mol%: 46.5 | Role: Sterol
Published C6mPhE-383 LNP composition
Component: C14-PEG2000 | mol%: 2.5 | Role: PEG lipid
Published C6mPhE-383 LNP composition
Component: Total | mol%: 100 | Role: Supporting Information §1.10
Reported observation
Reporter mRNA delivery At 0.05 mg/kg luciferase mRNA (1 µg) and 6 h after intramuscular dosing, the aroLNP series showed lymph-node transfection with less liver signal than the SM-102 comparator. C6mPhE-383 was selected for follow-up biodistribution experiments.
Reported observation
Distribution DiR-labeled C6mPhE-383 LNPs accumulated in draining iliac and inguinal lymph nodes with lower hepatic accumulation than SM-102 LNPs after intramuscular injection.
Reported observation
Vaccination In a mouse SARS-CoV-2 spike mRNA prime–boost study (0.25 mg/kg, 5 µg mRNA; doses 3 weeks apart), C6mPhE-383 LNPs produced anti-RBD IgG and antigen-responsive T-cell responses. Spleens and serum were assessed 2 weeks after boosting.
Reported observation
Systemic cytokines In a separate luciferase mRNA experiment, circulating IL-6, TNF and IFN-γ were lower for C6mPhE-383 LNPs than for the SM-102 LNP comparator under the reported conditions.